Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polyethyleneglycol-modified polypeptide capable of inhibiting nuclear factor-kappaB and application thereof

A technology of polyethylene glycol and nuclear factor, applied to non-active ingredient medical preparations, active ingredient-containing medical preparations, peptides, etc., to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2014-04-23
郭向华
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
The research on PEG modification of synthetic small molecule peptides started late, but it has attracted the attention of many researchers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] In vivo immune protection of polyethylene glycol-modified inhibitory nuclear factor-κB polypeptide in a collagen-induced mouse arthritis model

[0019] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of polyethylene glycol-modified inhibitory nuclear factor-κB polypeptide on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22 g, were randomly divided into 6 groups, namely normal control group, model control group, peptide inhibitor 1 low, middle and high dosage groups (5, 10 , 20mg / kg) and positive drug control group (methotrexate 2 mg / kg). In addition to the normal group, the mouse CIA model was established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid ...

Embodiment 2

[0024] In vivo protective effect of polyethylene glycol-modified inhibitory nuclear factor-κB polypeptide on adjuvanted rat arthritis animal model

[0025]To construct an animal model of adjuvant arthritis in rats, and study the therapeutic effect of polyethylene glycol-modified nuclear factor-κB polypeptide on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab. Animal Ltd, animal production license number: SCXK (Shanghai) 2008 -0016), male, with a body weight of 140 g-160 g, were randomly divided into 6 groups, namely the normal control group, the model control group, and the PEG-modified anti-nuclear factor-κB polypeptide low, medium and high dosage groups (5, 10, 20 mg / kg) and positive drug control group (methotrexate 1 mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacter...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, particularly a polyethyleneglycol-modified polypeptide capable of inhibiting nuclear factor-kappaB and preventing and treating rheumatoid arthritis. The sequence is mPEG-SC20k-KRSGGGFPAAV which is a brand-new sequence. The polyethyleneglycol-modified polypeptide capable of inhibiting nuclear factor-kappaB can be used for treating rheumatoid arthritis, and has potential value in developing new drugs.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to a nuclear factor-κB polypeptide inhibitor used for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in my country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age of women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61K38/08A61K47/48A61P29/00A61P19/02
Inventor 罗瑞雪
Owner 郭向华
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com